Regeneron Pharmaceuticals Inc (REGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Regeneron Pharmaceuticals Inc stock (REGN) is currently trading at $749.47. Regeneron Pharmaceuticals Inc PE ratio is 17.89. Regeneron Pharmaceuticals Inc PS ratio (Price-to-Sales) is 5.47. Analyst consensus price target for REGN is $873.78. WallStSmart rates REGN as Hold.
Regeneron Pharmaceuticals Inc (REGN) stock price prediction for 2030: Base case $695.36. Bull case $869.20. Bear case $521.52. See full REGN 2030 price forecast and methodology on WallStSmart.
- REGN PE ratio analysis and historical PE chart
- REGN PS ratio (Price-to-Sales) history and trend
- REGN intrinsic value — DCF, Graham Number, EPV models
- REGN stock price prediction 2025 2026 2027 2028 2029 2030
- REGN fair value vs current price
- REGN insider transactions and insider buying
- Is REGN undervalued or overvalued?
- Regeneron Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- REGN Piotroski F-Score and Altman Z-Score
- REGN analyst price target and Smart Rating
Regeneron Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
REGN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Regeneron Pharmaceuticals Inc (REGN)
REGN trades 166% above its Graham fair value of $281.93, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Regeneron Pharmaceuticals Inc (REGN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, profit margin. Concerns around revenue growth and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Regeneron Pharmaceuticals Inc (REGN) Key Strengths (4)
Keeps $31 of every $100 in revenue as net profit
90.91% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $23 kept per $100 revenue
Regeneron Pharmaceuticals Inc (REGN) Areas to Watch (6)
Earnings declining -2.60%, profits shrinking
Revenue growing slowly at 2.50% annually
Premium valuation at 5.5x annual revenue
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Fairly priced relative to book value
Supporting Valuation Data
Regeneron Pharmaceuticals Inc (REGN) Detailed Analysis Report
Overall Assessment
This company scores 58/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 3.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Profit Margin, Institutional Own., Market Cap. Profitability is solid with Operating Margin at 23.10%, Profit Margin at 31.40%.
The Bear Case
The primary concerns are EPS Growth, Revenue Growth, Price/Sales. Some valuation metrics including PEG Ratio (1.56), Price/Sales (5.47), Price/Book (2.48) suggest expensive pricing. Growth concerns include Revenue Growth at 2.50%, EPS Growth at -2.60%, which may limit upside. Profitability pressure is visible in Return on Equity at 14.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 14.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Profit Margin, Institutional Own.) and negatives (EPS Growth, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
REGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
REGN's Price-to-Sales ratio of 5.47x trades at a deep discount to its historical average of 12.08x (10th percentile). The current valuation is 82% below its historical high of 29.64x set in Apr 2007, and 47% above its historical low of 3.71x in Oct 2009.
WallStSmart Analysis Synopsis
Data-driven financial summary for Regeneron Pharmaceuticals Inc (REGN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Regeneron Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 14.3B with 3% growth year-over-year. Profit margins are strong at 31.4%, reflecting pricing power and operational efficiency.
Key Findings
Profit margin of 31.4% and operating margin of 23.1% demonstrate strong pricing power and operational efficiency.
Generating 922M in free cash flow and 1.2B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Regeneron Pharmaceuticals Inc.
Bottom Line
Regeneron Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(86 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:11:36 AM
About Regeneron Pharmaceuticals Inc(REGN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.